Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carninoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 8, 2006, Pages 1276-1280

  Ramalho, Fernando S ^a   Ramalho, Leandra N Z ^a   Della Porta, Livia ^a   Zucoloto, Sérgio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Immunohistochemistry; Liver; p63; Stem cell

Indexed keywords

CYTOKERATIN 19; PROTEIN P63;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STAINING; STEM CELL; TISSUE SECTION;

EID: 33745869108     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04309.x     Document Type: Article

References (26)

1. Strano S, Rossi M, Fontemaggi G et al. From p63 to p53 across p73. FEBS Lett. 2001; 490: 163-70.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 16: 307-10.
3. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001; 12: 337-49.
4. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 22: 708-13.
5. Yang A, Schweitzer R, Sun D et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 22: 714-18.
6. Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8: 494-501.
7. Irwin MS, Kaelin WG Jr. Role of the newer p53 family proteins in malignancy. Apoptosis 2001; 6: 17-29.
8. Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum. Pathol. 2001; 32: 1157-65.
9. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum. Pathol. 2002; 33: 158-64.
10. Nylander K, Vojtesek B, Nenutil R et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J. Pathol. 2002; 198: 417-27.
11. Pelosi G, Pasini F, Olsen Stenholm C et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J. Pathol. 2002; 198: 100-9.
12. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum. Pathol. 2002; 33: 921-6.
13. Tannapfel A, Schmelzer S, Benicke M et al. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. J. Pathol. 2001; 195: 163-70.
14. Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch. Pathol. Lab. Med. 2003; 127: 336-40.
15. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Sakon M, Matsuura N. Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness. Int. J. Mol. Med. 2001; 8: 67-71.
16. Hornick JL, Lauwers GY, Odze RD. Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am. J. Surg. Pathol. 2005; 29: 381-9.
17. Hurlimann J, Gardiol D. Immunohistochemistry in the differential diagnosis of liver carcinomas. Am. J. Surg. Pathol. 1991; 15: 280-8.
18. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum. Pathol. 2002; 33: 1175-81.
19. Haque S, Haruna Y, Saito K et al. Identification of bipotential progenitor cells in human liver regeneration. Lab. Invest. 1996; 75: 699-705.
20. Haruna Y, Saito K, Spaulding S, Nalesnik MA, Gerber MA. Identification of bipotential progenitor cells in human liver development. Hepatology 1996; 23: 476-81.
21. Sell S, Dunsford HA. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am. J. Pathol. 1989; 134: 1347-63.
22. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am. J. Pathol. 1996; 149: 1167-75.
23. Lee JH, Rim HJ, Sell S. Heterogeneity of the 'oval-cell' response in the hamster liver during cholangiocarcinogenesis following Clonorchis sinensis infection and dimethylnitrosamine treatment. J. Hepatol. 1997; 26: 1313-23.
24. Liu C, Wang J, Ou QJ. Possible stem cell origin of human cholangiocarcinoma. World J. Gastroenterol. 2004; 15: 3374-6.
25. Sasaki M, Tsuneyama K, Ishikawa A, Nakanuma Y. Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. Hum. Pathol. 2003; 34: 1337-44.
26. Chiorean MV, Guicciardi ME, Yoon JH, Bronk SF, Kaufmanns SH, Gores GJ. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int. 2004; 24: 687-95.